Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 2) 2001 No. 80
EXPLANATORY STATEMENT
STATUTORY RULES 2001 No. 80
Issued by the Authority of the Minister for Health and Aged Care
Health Insurance Act 1973
Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 2)
Section 133 of the Health Insurance Act 1973 (the Act) provides that the Governor-General may make regulations prescribing matters for the purpose of the Act.
The Act provides for the payment of professional services through Medicare benefits to all eligible persons.
Section 9 of the Act provides that Medicare benefits shall be calculated by reference to the fees for medical services (including pathology services) set out in the table.
Section 4A of the Act provides that a table of pathology services may be prescribed. The Health Insurance (Pathology Services Table) Regulations 2000, which commenced on 1 November 2000, prescribe such a table.
The amendment Regulations implement a number of changes to the Pathology Services Table as follows:
• a restructure of the Prostate Specific Antigen (PSA) test items and introduction of a new item;
• new items for testing for Antineutrophil Cytoplasmic Antibodies (ANCA) and accompanying new Rule. and
• a minor amendment to item 71109 to remove reference to all items now covered by the ANCA items and to clarify Rule 4 of the Rules of Interpretation.
The overall effect of the changes is anticipated to have no major financial implications and will be incorporated within the expenditure targets under the Pathology Quality and Outlays Agreement for 2000/2001.
The changes have been developed in cooperation with the two peak pathology professional bodies, the Royal College of Pathologists of Australasia and the Australian Association of Pathology Practices, through the Pathology Services Table Committee (PSTC).
Details of the regulations are set out in the Attachment.
The Regulations commenced on 1 May 2001.
ATTACHMENT
Regulation 1 cites the regulations as the Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 2).
Regulation 2 prescribes a commencement date of 1 May 2001.
Regulation 3 prescribes the amendments to the Health Insurance (Pathology Services Table) Regulations 2000. The changes under Regulation 3, Schedule 1 are:
• a restructure of Prostate Specific Antigen (PSA) items 66656 and 66659 with the introduction of a new item 66655 for clinically suspected prostatic disease. The new structure provides for more appropriate PSA testing without restricting access to this test;
• four new immunology items (71153 - 71159) for the measurement of Antineutrophil Cytoplasmic Antibodies (ANCA) in the assessment or diagnosis of systemic inflammatory disease or vasculitis. A new Rule of interpretation to accompany these new items to provide clarification;
• an amendment to immunology item 71109 by removing reference to glomerular basement membrane and neutrophil cytoplasm as they are covered in the new ANCA items; and
• an amendment to Rule 4 (1) to include reference to items 66503, 66506, 66509, 66512 and 66515. This rule covers the exemptions to Rule 3 and the amendment clarifies which items are exempted in the intensive care setting.
Overview
The Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 2) were enacted to update the fees for pathology services under the Health Insurance Act 1973. The regulations were issued by the Minister for Health and Aged Care and aim to address gaps in the existing Pathology Services Table by reconfiguring certain test items and introducing new ones to better align with current medical practices and diagnostic needs. These amendments were developed in collaboration with the Royal College of Pathologists of Australasia and the Australian Association of Pathology Practices through the Pathology Services Table Committee, ensuring that the changes are both clinically relevant and financially sustainable within the existing expenditure targets. The Regulations commenced on 1 May 2001, implementing a restructure of Prostate Specific Antigen (PSA) test items, introducing new items for Antineutrophil Cytoplasmic Antibodies (ANCA) testing, and making minor adjustments to existing items to improve clarity and accuracy in medical billing and service provision.
Scope and Application
The Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 2) applies to the framework established under the Health Insurance Act 1973 for the provision of Medicare benefits, particularly focusing on pathology services. These regulations govern the fees for medical services, including pathology services, that are payable under Medicare. They specifically amend the Pathology Services Table by restructuring the Prostate Specific Antigen (PSA) test items and introducing a new item for clinically suspected prostatic disease, adding new items for the measurement of Antineutrophil Cytoplasmic Antibodies (ANCA) in the assessment or diagnosis of systemic inflammatory disease or vasculitis, and making minor amendments to existing items to reflect current practices and technological advancements. The regulations are applicable nationally across Australia as they pertain to the federal system of Medicare benefits. They do not explicitly exclude any particular entities or individuals, but their application is inherently limited to services provided within the Medicare framework. The changes are intended to ensure that the benefits are calculated accurately and fairly, reflecting the latest medical practices and technological capabilities.
Key Provisions
The Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 2) (the Regulations) amend the existing Health Insurance (Pathology Services Table) Regulations 2000. The primary amendments are detailed in Regulation 3, Schedule 1 and include the restructuring of Prostate Specific Antigen (PSA) test items, the introduction of a new PSA test item for clinically suspected prostatic disease, the addition of new items for Antineutrophil Cytoplasmic Antibodies (ANCA) testing, and a minor amendment to an existing immunology item. These changes aim to enhance the appropriateness of PSA testing, provide new pathways for diagnosing systemic inflammatory diseases, and ensure clarity and consistency within the pathology services table.
The Regulations impose specific obligations on pathology service providers and medical practitioners. Pathology service providers must adhere to the restructured PSA test items and new ANCA testing items, ensuring that these services are rendered in accordance with the specified fees and conditions. Medical practitioners, when referring patients for these tests, must ensure they are eligible for Medicare benefits and that the tests are medically necessary. Both parties must comply with the updated Rules of Interpretation to correctly apply the new and amended items.
Failure to comply with the provisions of the Regulations can result in financial penalties for both service providers and medical practitioners. Specifically, inaccurate billing for services not covered by the Pathology Services Table, or overcharging for services, can result in the recovery of any overpayments by the Commonwealth. Additionally, there may be administrative actions taken against non-compliant service providers, including potential exclusion from the Medicare provider scheme. While the Regulations do not explicitly outline criminal penalties, breaches of Medicare billing rules can lead to criminal charges under the Health Insurance Act 1973 if the breach is deemed wilful or negligent.
The Regulations are designed to ensure that the Pathology Services Table remains an accurate and fair representation of the services provided under the Medicare scheme. By restructuring and updating specific items, the Regulations aim to enhance the quality of care and ensure appropriate access to essential pathology services. Compliance with these Regulations is crucial for both pathology service providers and medical practitioners to maintain eligibility for Medicare benefits and avoid financial and administrative repercussions.